Cerezyme®
Understanding Cerezyme®
Cerezyme® (imiglucerase) is an enzyme replacement therapy (ERT) used to treat Gaucher disease type 1, a rare genetic disorder caused by a deficiency of the enzyme glucocerebrosidase. This deficiency leads to the accumulation of glucocerebroside, a fatty substance, in vital organs such as the liver, spleen, and bone marrow, resulting in severe complications. Cerezyme® is a lifelong therapy that helps manage symptoms and prevent complications in patients with Gaucher disease type 1. Early treatment is essential to achieve better long-term outcomes and improve quality of life.
How Cerezyme® Works:
- Replaces the missing glucocerebrosidase enzyme
- Helps break down glucocerebroside, reducing its buildup in organs
- Improves symptoms such as organ enlargement, anemia, and bone pain
FDA Approval:
- Cerezyme® (imiglucerase): Approved in 1994
For more information, please visit the Cerezyme® patient website and speak with your healthcare provider to determine if Cerezyme® is the right treatment option for you.
Referral Form: |
WHAT IT TREATS: |
MANUFACTURER: Genzyme Corporation |
CLASS: Enzyme Replacement Therapy (ERT) |
|
PRESCRIBED BY:
|
|
HOW ADMINISTERED: IV Infusion |
|
FREQUENCY: Three times a week to once every two weeks, based upon disease severity. |
Length of infusion: Generally one to two hours. In some cases, more than two hours. |
FOR MORE INFORMATION: |
Related drugs
